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ABSTRACT 
A wide variety of endogenous carboxylic acids and xenobiotics are conjugated with 
amino acids, before excretion in urine or bile. The conjugation of carboxylic acids and 
bile acids with taurine and glycine has been widely characterized and de-novo 
synthesized bile acids are conjugated to either glycine or taurine in peroxisomes. 
Peroxisomes are also involved in the oxidation of several other lipid molecules, such 
as very long chain acyl-CoAs, branched chain acyl-CoAs and prostaglandins. In this 
study we have now identified a novel peroxisomal enzyme called acyl-CoA:amino 
acid N-acyltransferase (ACNAT1). Recombinantly expressed ACNAT1 acts as an 
acyltransferase that efficiently conjugates very long-chain and long-chain fatty acids 
to taurine. The enzyme shows no conjugating activity with glycine, showing that it is 
a specific taurine conjugator. Acnat1 is mainly expressed in liver and kidney and the 
gene is localized in a gene cluster, together with two further acyltransferases, one of 
which conjugates bile acids to glycine and taurine. In conclusion, these data describe 
ACNAT1 as a new acyltransferase, involved in taurine conjugation of fatty acids in 
peroxisomes, identifying a novel pathway for production of N-acyltaurines as 
signaling molecules or for excretion of fatty acids.  
 
Key words: acyl-CoA, fatty acid amide hydrolase, N-acyltaurine. 
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INTRODUCTION 
 
The conjugation of xenobiotics to amino acids is one of the first described drug 
metabolizing reactions known and dates back to 1842 (1). It is now well established 
that a wide variety of endogenous carboxylic acids and xenobiotics are conjugated 
with amino acids in reactions catalyzed by different acyltransferase enzymes (2). 
These include both endogenous compounds like bile acids, fatty acids, and various 
drugs containing carboxyl groups such as clofibric acid and lovastatin (3-7). Amino 
acid conjugation occurs in a two-step process. The first step involves activation of the 
carboxylic acid to the CoA ester which is catalyzed by acyl-CoA synthetases (8). The 
second step, the conjugation reaction, is catalyzed by an acyl-CoA:amino acid N-
acyltransferase (EC 2.3.1). While the conjugation of carboxylic acids and bile acids 
with taurine and glycine is the most common, L-asparagine and L-glutamine have 
also been shown to act as weak acceptors (9). The conjugation of carboxylic acids to 
amino acids is important as it increases the solubility of these compounds, allowing 
them to be excreted in urine or bile, and acts as a detoxification system for excretion 
of xenobiotics. The conjugation of xenobiotics is mainly linked to mitochondria and 
glycine conjugating enzymes have been identified in this organelle in several species 
(9-12). In some cases however, the metabolism of xenobiotic acyl compounds also 
occurs in peroxisomes (13).  
 
Peroxisomes are organelles that are present in virtually all eukaryotic cells and are 
involved in the metabolism of a variety of lipids such as very long chain fatty acids, 
dicarboxylic acids, prostaglandins, leukotrienes, branched-chain fatty acids, 
xenobiotics and bile acids (14). In peroxisomes, many of these lipids are mainly 
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oxidized by the peroxisomal β-oxidation system, where they are chain-shortened, 
with the concomitant release of acetyl-CoA. In the case of primary bile acid synthesis, 
trihydroxycholestanoic acid and dihydroxycholestanoic acid are activated to their 
corresponding CoA esters by very long chain acyl-CoA synthetase (VLCS) (15) and 
then undergo one cycle of β-oxidation in peroxisomes, to produce choloyl-CoA and 
chenodeoxycholoyl-CoA respectively (16). These bile acids are then amidated (or 
conjugated) to either glycine or taurine by an enzyme named bile acid-CoA:amino 
acid N-acyltransferase (BACAT). This conjugation with the amino acids glycine or 
taurine plays several important roles in the biology of bile acids, such as excretion of 
bile acids and cholesterol in bile, and increases the detergent properties of bile acids 
in the intestine. Recent data has shown that recombinant human BACAT can also 
conjugate fatty-acyl-CoAs to glycine (5) and taurine (O’Byrne et al, unpublished 
results).  
 
BACAT has been characterized from several species and shows large species 
differences in the use of glycine or taurine as an acceptor molecule (3-5, 17).  
BACAT is related to a family of proteins called the Type-I acyl-CoA thioesterases 
(ACOTs) (for review see (18)). These ACOT enzymes show approximately 40-45% 
sequence identity at amino acid level to the BACAT enzyme (3, 4). Acyl-CoA 
thioesterase enzymes catalyze the hydrolysis of CoA esters of fatty acids to the free 
fatty acid and coenzyme A (CoA), whereas BACAT conjugates bile acids and fatty 
acids to glycine and taurine, using the bile acid-CoA or acyl-CoA moiety as a 
substrate. Using Blast Searches, we have now identified a novel peroxisomal enzyme 
in mouse that we name acyl-CoA:amino acid N-acyltransferase 1 (ACNAT1), which 
is related to both BACAT and the Type-I ACOTs. In this study, we have 
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characterized this novel peroxisomal acyltransferase and show that it efficiently 
conjugates long-chain fatty acids to taurine.  
 
MATERIALS AND METHODS 
 
Chemicals- All commercially available acyl-CoAs used in this study were from 
Sigma-Aldrich Inc. (St. Louis, MO, USA).  
 
Animals and treatments- Tissues used in this study were excised from adult male 
Sv/129 mice. Animals were sacrificed by CO2 asphyxiation followed by cervical 
dislocation. Tissues were excised and stored at –70oC for preparation of total RNA.  
 
Cloning and expression of Acnat1 - The open reading frame (ORF) for Acnat1 was 
derived from genomic databases and expressed sequence tags (ESTs) from the mouse 
EST database (www.ncbi.nlm.nih.gov). The Acnat1 ORF was amplified from mouse 
kidney total RNA using the following primers: 5’-
CTCCTCTAGAATGATGATCCAGTTGATAGC -3’ & 5’-
CTCCTCTAGATTAGAGTTTGCTTCCGGATTG-3’ (Cybergene AB, Novum, Sweden) 
with the addition of Xba I sites (indicated in bold). The PCR product was cloned into 
the Xba I site of the pMAL-c2X vector (New England Biolabs Inc., Beverly, MA, 
USA) and the plasmid fully sequenced. BL21(DES3)pLysS cells (Novagen Inc., 
Madison, WI, USA) were transformed with the pMal-c2X and overnight cultures 
were transferred to 500 ml Luria-Bertani medium containing 1 g of glucose and were 
grown at 37oC until an OD600nm of about 0.5 was reached. Protein expression was 
induced by addition of 0.1 mM isopropyl-1-thio-β-D-galactopyranoside for 17 h at 
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20oC after which the bacteria were harvested by centrifugation, resuspended in 20 ml 
cold column buffer (20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA) and 
stored at -20˚C.  
 
Purification of recombinant ACNAT1 - Bacteria were sonicated in pulses of 12 x 5 sec 
at 5 sec intervals and centrifuged at 9,000 x g at 4˚C for 30 min. The supernatant was 
filtered through a 0.22 µm filter and recombinant protein purified using amylose resin 
(New England Biolabs Inc. Beverly, MA, USA). The recombinant protein was eluted 
with column buffer containing 10 mM maltose.  
 
Electrospray mass spectrometry (ES-MS) analysis- Incubation mixtures were set up 
containing various acyl-CoAs (20 µM), 5 µg recombinant ACNAT1 and taurine (50 
mM) in 50 mM potassium phosphate buffer, pH 8. Bovine serum albumin (BSA) was 
added in a molar ratio ranging from 1:1.2 – 1:5.7 BSA:acyl-CoA. Km and Vmax were 
determined using 5-50 µM palmitoyl-CoA. Incubations were carried out for 5 min at 
37˚C after which the samples were purified using Sepac C18 columns (International 
Sorbent Technologies, UK) essentially as described in (5), but the column was 
washed with 3 ml water and samples eluted with 3 ml methanol A standard of 
nonadecanoic acid was added to the incubation mixtures prior to column purification. 
The eluate was dried under nitrogen and samples reconstituted in ~100 µl methanol. 
The samples were injected into a Quattro Micro triple quadrupole mass spectrometer 
(Micromass, Manchester, UK) at a flow rate of 10 µl/min. Mass spectra were acquired 
in the negative ion mode over a mass scan range of m/z 100-1000 for 2 min at a scan 
rate of 4 sec per scan.   
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Localization of ACNAT1 in peroxisomes using green fluorescent fusion protein and 
cell transfections- Oligonucleotides were designed based on the sequence of the ORF 
for Acnat1 for cloning as a fusion protein in-frame with green fluorescent protein 
(GFP). The ORF of Acnat1 was amplified by RT-PCR from mouse kidney total RNA 
using the following primers: 5’-CATATGATGATCCAGTTGATAGCC-3’ and 5’-
CATATGTACTCTGGCATGGACACTCT-3’. PCR was performed in a Perkin-
Elmer 2600 using the One Step RNA PCR kit (AMV) (Takara Biomedical, Shiga, 
Japan) and the PCR product was cloned into the pcDNA3.1/NT-GFP vector 
(Invitrogen), in-frame with GFP. Sequence analysis was performed using Big Dye 
Terminator Ready Reaction kit (Applied Biosystems Inc, CA, USA). Human skin 
fibroblasts from a control subject and a Zellweger patient were grown as described 
previously (19). The cells were grown overnight in 60-mm dishes on glass coverslips 
and were transfected with 10 µg of ACNAT1/NT-GFP plasmid using the calcium 
phosphate method. The cells were fixed and processed for immunofluorescence 
microscopy as described in (19).  
 
Tissue expression of Acnat1 and fatty acid amide hydrolase (Faah) using 
Quantitative-PCR or Reverse Transcriptase-PCR- Total RNA was isolated from 
various mouse tissues using Trizol reagent (Invitrogen Corporation, CA, USA). Total 
RNA was treated with DNase 1 (Promega Corporation, Madison, WI, USA) prior to 
cDNA synthesis. RNA from 3 individual animals was pooled for cDNA synthesis and 
the synthesis was performed using 1 µg of total RNA using Taqman Reverse 
Transcription reagents (Applied Biosystems Inc). Quantitative-PCR was performed in 
an ABI Prism 7000 sequence detection system, using TaqMan universal PCR master 
mix (Applied Biosystems Inc.). An Acnat1 amplicon in the 5’- UTR was amplified 
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using the following primers 5’-GAGGCAGCAACTGTGGTGACT-3’ and                                               
5’-TGAGACTGTATGTTTTCCTTGCTCTAC-3’ and a probe with a 5’FAM and 
3’dabcyl of 5’-CGGTCATGGAGGCGGAGTGA3’. As endogenous controls an 
amplicon of 18S and mouse β-actin was used, using the pre-developed TaqMan Assay 
Reagent for 18S rRNA or β-actin (Applied Biosystems Inc.). The Q-PCR was run in 
single-plex in triplicate for each sample. Data was analyzed using the ABI Prism 7000 
SDS software and the average CT value per triplicate was used to calculate the relative 
amounts of Acnat1 mRNA using the 2-∆∆CT  method. An amplicon of mouse FAAH 
was amplified using the following primers 5’-
GAAAGGCCTGGGAAGTGAACAAAG-3’ and 5’-
CCATGGGGCCAACAGAAAG-3’. RT-PCR was carried out on total RNA from 
mouse tissues (pooled from three animals) using One-Step RT-PCR kit (Takara 
Biomedicals) using an annealing temperature of 55˚C and 27 cycles.  
 
RESULTS 
 
Identification of Acnat1 - We previously identified and cloned a novel gene family of 
ACOTs in mouse, with members identified in cytosol (Acot1), mitochondria (Acot2) 
and peroxisomes (Acot3, Acot4, Acot5, Acot6) (20-23). When these genes were 
identified, they showed homology only to Bacat, an enzyme involved in the 
conjugation of bile acids. Following the advent of genome sequencing and using EST 
database searches, we have now identified two further genes which were mapped to 
mouse chromosome 4 B3, and found to be located in a small gene cluster within 100 
kb with the mouse Bacat (Fig. 1A). These newly identified genes were named Acnat1 
and Acnat2 and are both encoded by 3 exons, which is similar to the exon pattern in 
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Bacat and the Type-I Acot genes (20). In this study, we have characterized the 
ACNAT1 in detail. Alignment of the amino acid sequence of ACNAT1 to mouse 
BACAT shows that this protein is approximately 52% identical to BACAT (Fig. 1B). 
The ACNAT1 also shows approximately 45% sequence identity to ACOT enzymes, 
which act as thioesterases, but is more closely related to BACAT, a conjugating 
enzyme. Characterization of the active site amino acids of the Type-I ACOTs and 
BACAT revealed a catalytic triad consisting of a nucleophilic serine residue in the 
ACOT enzymes (24), or a nucleophilic cysteine residue in BACAT (5, 25), a histidine 
and an aspartic acid. The amino acid residues of the catalytic triad are all conserved in 
ACNAT1, with the ACNAT1 active site containing a serine in a SerXaaSerXaaGly 
motif (Fig. 1B). 
 
ACNAT1 is localized in Peroxisomes- ACNAT1 contains the tripeptide serine-lysine-
leucine (-SKL) at its carboxyterminal, which is the consensus sequence of the 
peroxisomal type 1 targeting signal that targets proteins to peroxisomes (26). To test 
if ACNAT1 is indeed peroxisomal, we expressed the protein in-frame with GFP, 
leaving the carboxyterminal –SKL accessible. ACNAT1 was expressed in control 
fibroblasts and fibroblasts from a Zellweger patient, which are unable to import 
peroxisomal matrix proteins. Immunofluorescence microscopy revealed a punctate 
pattern of expression in control fibroblasts, indicative of a peroxisomal localization 
(Fig. 2A). When the same construct was transfected into Zellweger fibroblasts, this 
resulted in a diffuse GFP pattern, showing that the protein was not imported into 
peroxisomes but remained in cytosol (Fig. 2B).  
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ACNAT1 is an acyltransferase that can conjugate fatty acids to taurine – The 
production of soluble protein for ACNAT1 proved difficult and following the use of 
several bacterial expression systems, the protein was expressed as a fusion protein 
with maltose binding protein (using the pMal-c2x vector), which resulted in the 
production of soluble protein. ACNAT1 shows homology to both BACAT and the 
Type-I ACOTs, and since acyl-CoAs are substrates for the Type-I ACOTs (21, 22, 24, 
27, 28) and both acyl-CoAs and bile acid-CoAs are substrates for BACAT (3-5) we 
hypothesized that ACNAT1 may be active on either acyl-CoAs and/or bile acid-
CoAs. While the Type-I ACOTs hydrolyze acyl-CoAs, BACAT conjugates fatty 
acids and bile acids to taurine and glycine, using the CoA moiety. Initially, incubation 
of recombinant ACNAT1 for 4 h with myristoyl-CoA (C14:0-CoA) in the presence of 
taurine resulted in efficient conjugation of myristic acid to form N-myristoyltaurine 
(Fig. 3A). The specificity of the reaction was verified by incubation of myristoyl-CoA 
and recombinant ACNAT1 in the absence of taurine, which showed no conjugation 
activity, but only hydrolysis of the CoA ester (Fig. 3B). Further characterization of 
ACNAT1 as an acyltransferase was carried out by incubating recombinant ACNAT1 
for 5 min with various long-chain acyl-CoAs. ACNAT1 efficiently conjugated acyl-
CoAs of C12:0-CoA to C24:0-CoA to taurine, suggesting that it acts as a long-chain 
fatty acid conjugating enzyme (Fig. 4A). Kinetic characterization of ACNAT1 was 
carried out using C16:0-CoA (palmitoyl-CoA) as substrate and the Km and Vmax were 
determined to be 11 µM and 159.5 nmol/min/mg, respectively (Fig. 4B). Incubation 
of recombinant ACNAT1 with CoA esters of the primary bile acids choloyl-CoA and 
chenodeoxycholoyl-CoA resulted in some conjugation of these substrates with 
taurine, however, this was very low compared with fatty acid conjugation (data not 
shown). Therefore ACNAT1 acts as an acyltransferase, conjugating very long-chain 
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and long-chain fatty acids to taurine. ACNAT1 showed no conjugation activity in the 
presence of glycine, confirming that it is a taurine conjugating enzyme.  
 
Tissue expression of Acnat1 and mouse Faah - Quantative PCR was carried out to 
examine the tissue expression of Acnat1 in mouse. Acnat1 was mainly expressed in 
liver and kidney, with low expression in adrenal and little or no expression in other 
tissues examined (Fig. 5A). FAAH has previously been identified as an N-acyltaurine 
hydrolyzing enzyme (29, 30) and we therefore examined the expression of Faah in 
various mouse tissues. Reverse transcriptase PCR (RT-PCR) showed that Faah was 
mainly expressed in liver, brain, testis and kidney (Fig. 5B), showing co-expression 
with Acnat1 in liver and kidney. We also examined the regulation of Acnat1 by 
fasting and treatment with Wy-14,643, a peroxisome proliferator, but Acnat1 was not 
regulated at mRNA level by either of these treatments (data not shown). 
 
DISCUSSION 
 
The identification of ACNAT1 is the first description of a specific fatty acid taurine 
conjugating enzyme and long chain acyl-CoA:amino acid N-acyltransferase. Its 
identification is timely in view of the very recent detection of taurine conjugated fatty 
acids (N-acyltaurines) as a novel class of endogenous lipids. These N-acyltaurines 
(NATs) were detected in brain, spinal cord, testes and liver of mice, using an LC-MS 
based analytical method termed Discovery Metabolite Profiling (DMP) (29, 30). 
Saghatelian et al used the DMP method to identify the physiological substrate for the 
fatty acid amide hydrolase (FAAH), an enzyme that degrades the endocannabinoid 
family of signaling lipids. The study identified metabolites that differed between 
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FAAH wild-type and knockout animals and it was shown that NATs were elevated 
15-40 fold in CNS tissues from FAAH knockout mice (29). The taurine conjugated 
fatty acids detected were mainly of 16 to 26 carbon atoms in length, with the most 
prevalent being C16:0, C18:0, C22:0 and C24:0 in wild type mice (29), similar to the chain-
length specificity of ACNAT1 now identified. The tissue expression of the Faah in 
this study shows that both Acnat1 and Faah are co-expressed in liver and kidney. 
FAAH has been shown to hydrolyze NATs back to the free fatty acid and taurine, 
with the activity varying depending on the chain length of the NAT, with C18:1 NAT 
being a better substrate for FAAH than C24 NAT (29, 30). This hydrolysis by FAAH 
could account for the low levels of NATs in-vivo, which are in the pmol/g range in 
brain, CNS, testes and liver, however these rise to nmol/g tissue in the CNS and 
spinal cord in the FAAH knockout mouse model (29). Acnat1 is mainly expressed in 
liver and kidney and there was only very weak mRNA expression in mouse whole 
brain, indicating that it is unlikely that ACNAT1 produces NATs in-situ in the CNS. 
Alternatively these NATs may be synthesized peripherally in the liver and kidney and 
could then be transported to the CNS. It has been hypothesized that a similar situation 
could exist in relation to glycine conjugates of fatty acids (N-acylglycines) and that 
hepatically derived NATs may be amidated by the bifunctional peptidylglycine α-
amidating enzyme (α-AE) and then cross the blood-brain barrier (31). Recently 
however, glycine conjugates of arachidonic acid have been detected in bovine and rat 
brain and are synthesized in-situ in rat brain as bioactive molecules that inhibit pain 
(32). This indicates that brain contains a distinct enzyme that can synthesize N-
acylglycines. It is not yet known if brain contains a distinct taurine conjugating 
enzyme responsible for synthesis of NATs in-situ in the CNS, or if these are 
synthesized by ACNAT1 in liver/kidney and transported to the CNS. 
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The fact that ACNAT1 is a peroxisomal enzyme raises the question of the role of 
ACNAT1 in this organelle. Peroxisomes are associated with the metabolism of 
several xenobiotic acyl compounds (13), together with the β-oxidation of very long-
chain fatty acids, bile acid intermediates, and α-oxidation and β-oxidation of 
branched chain fatty acids (33). Prostaglandins are also chain shortened in 
peroxisomes, followed by excretion in urine (34). Interestingly, novel taurine 
conjugated metabolites of prostaglandin E2 were identified in rat hepatocytes 
following β-oxidation (35), suggesting that partial β-oxidation of prostaglandins in 
peroxisomes followed by taurine conjugation of the metabolites is a means of 
excreting these lipids. Our finding here of a peroxisomal fatty acid taurine 
conjugating enzyme suggests that the entire process of partial β-oxidation followed by 
taurine conjugation occurs in peroxisomes. Similarly, bile acid intermediates are 
(side) chain shortened by β-oxidation followed by taurine (and glycine) conjugation 
in peroxisomes, which is the final step in de-novo bile acid synthesis and following 
conjugation, these bile acids are excreted into bile. Again, this conjugation results in 
more polar compounds for excretion and increases the detergent properties of bile 
acids in the intestine. Thus peroxisomal taurine conjugation of prostaglandins and bile 
acids results in products that are more easily excreted. In a similar way, the formation 
of long chain NATs by ACNAT1 in peroxisomes would also result in the production 
of more polar lipids for excretion. Although levels of NATs are low under normal 
conditions, it may be that ACNAT1 is more active under pathophysiological 
conditions where high levels of potentially toxic fatty acids prevail and the 
conjugation of these fatty acids to taurine would provide an excretory pathway in bile 
or urine (Fig. 6). In peroxisomes, carnitine is involved in the transfer of β-oxidation 
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products to the mitochondria for further oxidation and several peroxisomal carnitine 
acyltransferase enzymes have been identified (36, 37), These carnitine 
acyltransferases have a similar catalytic mechanism to ACNAT1, by catalyzing the 
transfer of the acyl moiety of acyl-CoAs to carnitine, the acceptor. However, these 
acyltransferases are only active on medium- and short-chain fatty acids, while 
ACNAT1 is active on long-chain and very long-chain fatty acids. Thus the formation 
of NATs may also allow fatty acids to be transferred within the cell, in a similar 
manner to acylcarnitines. Under pathophysiological conditions when long chain acyl-
CoAs accumulate in mitochondria, they are converted to acylcarnitines that leave the 
mitochondria and can readily be assayed in blood (38). Interestingly, acylcarnitines 
are also secreted in bile and it was shown that these bile acylcarnitines were elevated 
in mice deficient in mitochondrial long-chain and very long-chain acyl-CoA 
dehydrogenases (39). Thus, a fatty acid taurine conjugating system in peroxisomes 
may function in analogy to the mitochondrial carnitine acyltransferase system in 
mitochondria to eliminate fatty acids under conditions of fatty acid overload. 
 
From an evolutionary point of view, ACNAT1 is related to both the BACAT enzyme 
and to a family of enzymes called Type-I acyl-CoA thioesterases (ACOTs) (for 
review see (18)) and is found in a novel gene cluster of acyltransferases on 
chromosome 4 B3 in mouse, together with BACAT. Several Type-I ACOT enzymes 
have been identified in peroxisomes and hydrolyze the acyl-CoA moiety of long-
chain fatty acids, medium-chain fatty acids, and succinyl-CoA, to the free acid and 
coenzyme A, and therefore function in terminating chain shortening of various 
carboxylic acids to promote transport out of the peroxisome (21-23). As stated 
previously, BACAT functions in the conjugation of bile acids and fatty acids to 
  
15
taurine and glycine. Therefore ACNAT1 has evolved into an enzyme that shares 
characteristics of both the ACOT and BACAT enzymes – it utilizes ACOT substrates 
(acyl-CoA) and the BACAT conjugation acceptor molecule (taurine). A further gene 
was identified on mouse chromosome 4 B3 that encodes a protein that is 92% 
identical to ACNAT1, which we named Acnat2. Although we have not as yet been 
able to identify the substrate for ACNAT2, we propose that also Acnat2 encodes an 
acyltransferase, given the very high percentage sequence identity to Acnat1. Thus 
Bacat, Acnat1 and Acnat2 comprise a novel gene cluster involved in conjugation 
processes for elimination of metabolites. As ACNAT1 and the ACOTs utilize the 
same substrate (acyl-CoAs) it is easy to envisage competitive or complementary 
functions for the two enzyme systems (Fig. 6). However, in general peroxisomal 
ACOTs show somewhat lower Km-values for long-chain acyl-CoAs than ACNAT1 (4 
µM for ACOT3 vs 11 µM for ACNAT1 with palmitoyl-CoA), suggesting that 
ACNAT1 will ‘kick-in’ when intra-peroxisomal acyl-CoA concentrations rise. Bile 
acid conjugates act as ligands for the farnesoid X receptor (FXR) (40-42), a nuclear 
receptor involved in regulation of bile acid and carbohydrate metabolism. Fatty acids 
and acyl-CoAs also act as agonists/antagonists for the peroxisome proliferator-
activated receptor alpha (PPARα) (43-46), which regulates numerous pathways of 
lipid metabolism. It will be interesting to elucidate if NATs can act as 
agonists/antagonists for nuclear receptors and if ACNAT1 can function in controlling 
levels of intracellular signaling molecules.  
   
In conclusion, we have identified ACNAT1 in mouse as a novel enzyme involved in a 
new pathway of taurine conjugation of fatty acids in peroxisomes. The identification 
of these taurine conjugates in the CNS and liver as novel metabolites (29) opens up a 
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new field of research in elucidating pathways for excretion of NATs, or alternatively 
the discovery of new metabolic pathways for production of signaling molecules. It 
will be interesting to examine if these NATs can act as signaling molecules in various 
pathways in liver or CNS, or whether they, like glycine and taurine conjugates of bile 
acids, may act as agonists/antagonists for nuclear receptors. 
  
17
REFERENCES 
 
1. Keller, W. (1842) On the conversion of benzoic acid into hippuric acid. Ann. 
Chem. Pharm. 43, 108 
2. Vessey, D. A. (1997) Enzymes involved in the formation of amide bonds. In 
In Comprehensive Toxicology (Guengerich, F. P., ed) Vol. 3 pp. 455-475, 
Elsevier Science, Oxford, England. 
3. Falany, C. N., Johnson, M. R., Barnes, S., and Diasio, R. B. (1994) Glycine 
and taurine conjugation of bile acids by a single enzyme. Molecular cloning 
and expression of human liver bile acid-CoA:amino acid N-acyltransferase. J. 
Biol. Chem. 269, 19375-19379 
4. Falany, C. N., Fortinberry, H., Leiter, E. H., and Barnes, S. (1997) Cloning, 
expression, and chromosomal localization of moue liver bile acid-CoA:amino 
acid N-acyltransferase. J. Lipid Res. 38, 1139-1148 
5. O'Byrne, J., Hunt, M. C., Rai, D. K., Saeki, M., and Alexson, S. E. H. (2003) 
The human bile acid-CoA:amino acid N-acyltransferase functions in 
conjugation of fatty acids to glycine. J. Biol. Chem. 278, 34237-34344 
6. Halpin, R. A., Ulm, E. H., Till, A. E., Kari, P. H., Vyas, K. P., Hunninghake, 
D. B., and Duggan, D. E. (1993) Biotransformation of lovastatin V. species 
differences in In Vivo metabolite profiles of mouse, rat, dog and human. Drug 
Metab. Dispos. 21, 1003-1011 
7. Emudianughe, T. S., Caldwell, J., Sinclair, K. A., and Smith, R. L. (1983) 
Species differences in the matabolic conjugation of clofibric acid and 
clofibrate in laboratory animals and man. Drug Metab. Dispos. 11, 97-102 
8. Knights, K. M. (1998) Role of hepatic fatty acid:coenzyme A ligases in the 
metabolism of xenobiotic carboxylic acids. Clin. Exp. Pharmacol. Physiol. 10, 
776-782 
9. Nandi, D. L., Lucas, S. V., and Webster, L. T. (1979) Benzoyl-Coenzyme 
A:Glycine N-acyltransfrase and Phenylacetyl-Coenzyme A:glycine N-
acyltransferase from bovine liver mitochondria. J. Biol. Chem. 254, 7230-
7237 
10. Kelley, M., and Vessey, D. A. (1993) Isolation and characterization of 
mitochondrial acyl-CoA:glycine N-acyltransferases from kidney. J. Biochem. 
(Tokyo) 8, 63-69 
11. Mawal, Y. R., and Qureshi, I. A. (1994) Purification to homogeneity of 
mitochondrial acyl CoA:glycine N-acyltransferase from human liver. 
Biochem. Biophys. Res. Commun. 205, 1373-1379 
12. Asaoka, K. (1991) Enzymes that metabolize acyl-coenzyme A in the monkey - 
their distribution, properties and roles in an alternative pathway for the 
excretion of nitrogen. Int. J. Biochem. 23, 429-434 
13. Suga, T. (2003) Drug metabolism in peroxisomes: Involvement of 
peroxisomal β-oxidation system in the oxidative chain-shortening of 
xenobiotic acyl compounds. Drug Metab. Pharmacokin. 18, 155-162 
14. Van Veldhoven, P. P., and Mannaerts, G. P. (1999) Role and organization of 
peroxisomal β-oxidation. Adv. Exp. Med. Biol. 466, 261-272 
15. Mihalik, S. J., Steinberg, S. J., Pei, Z., Park, J., Kim, D. G., Heinzer, A. K., 
Dacremont, G., Wanders, R. J. A., Cuebas, D. A., Smith, K. D., and Watkins, 
P. A. (2002) Participation of two members of the very long-chain acyl-CoA 
  
18
synthetase family in bile acid synthesis and recycling. J. Biol. Chem. 277, 
24771-24779 
16. Russell, D. W. (2003) The enzymes, regulation, and genetics of bile acid 
synthesis. Annu. Rev. Biochem. 72, 137-174 
17. He, D., Barnes, S., and Falany, C. N. (2003) Rat liver bile acid CoA:amino 
acid N-acyltransferase: expression, characterization, and peroxisomal 
localization. J. Lipid Res. 44, 2242-2249 
18. Hunt, M. C., and Alexson, S. E. H. (2002) The role acyl-CoA thioesterases 
play in mediating intracellular lipid metabolism. Prog. Lipid Res. 41, 99-130 
19. Hunt, M. C., Solaas, K., Kase, B. F., and Alexson, S. E. H. (2002) 
Characterization of an acyl-CoA thioesterase that functions as a major 
regulator of peroxisomal lipid metabolism. J. Biol. Chem. 277, 1128-1138 
20. Hunt, M. C., Nousiainen, S. E. B., Huttunen, M. K., Orii, K., Svensson, L. T., 
and Alexson, S. E. H. (1999) Peroxisome proliferator-induced long chain acyl-
CoA thioesterases comprise a highly conserved novel multi-gene family 
involved in lipid metabolism. J. Biol. Chem. 274, 34317-34326 
21. Westin, M. A. K., Alexson, S. E. H., and Hunt, M. C. (2004) Molecular 
cloning and characterization of two mouse peroxisome proliferator-activated 
receptor alpha (PPARα)-regulated peroxisomal acyl-CoA thioesterases. J. 
Biol. Chem. 279, 21841-21848 
22. Westin, M. A. K., Hunt, M. C., and Alexson, S. E. H. (2005) The 
identification of a succinyl-CoA thioesterase suggests a novel pathway for 
succinate production in peroxisomes. J. Biol. Chem. 280, 38125-38132 
23. Hunt, M. C., Rautanen, A., Westin, M. A. K., Svensson, L. T., and Alexson, S. 
E. H. (2006) Analysis of mouse and human acyl-CoA thioesterase (ACOT) 
gene clusters shows that convergent functional evolution results in a reduced 
number of peroxisomal ACOTs. FASEB J. In press. 
24. Huhtinen, K., O'Byrne, J., Lindquist, P. J. G., Contreras, J. A., and Alexson, S. 
E. H. (2002) The peroxisome proliferator-induced cytosolic type I acyl-CoA 
thioesterase (CTE-I) is a serine-histidine-aspartic acid alpha/beta hydrolase. J. 
Biol. Chem. 277, 3424-3432 
25. Sfakianos, M. K., Wilson, L., Sakalian, M., Falany, C. N., and Barnes, S. 
(2002) Conserved residues in the putative catalytic triad of human bile acid 
coenzyme A:amino acid N-acyltransferase. J. Biol. Chem. 277, 47270-47275 
26. Gould, S. J., Keller, G. A., Hosken, N., Wilkinson, J., and Subramani, S. 
(1989) A conserved tripeptide sorts proteins to peroxisomes. J. Cell Biol. 108, 
1657-1664 
27. Lindquist, P. J. G., Svensson, L. T., and Alexson, S. E. H. (1998) Molecular 
cloning of the peroxisome proliferator-induced 46-kDa cytosolic acyl-CoA 
thioesterase from mouse and rat liver. Eur. J. Biochem. 251, 631-640 
28. Yamada, J., Matsumoto, I., Furihata, T., Sakuma, M., and Suga, T. (1994) 
Purification and properties of long-chain acyl-CoA hydrolases from the liver 
cytosol of rats treated with peroxisome proliferator. Arch. Biochem. Biophys. 
308, 118-125 
29. Saghatelian, A., Trauger, S. A., Want, E. J., Hawkins, E. G., Siuzdak, G., and 
Cravatt, B. J. (2004) Assignment of endogenous substrates to enzymes by 
global metabolite profiling. Biochemistry 43, 14332-14339 
30. Saghatelian, A., and Cravatt, B. J. (2005) Discovery metabolite profiling - 
forging functional connections between the proteome and metabolome. Life 
Sciences 77, 1759-1766 
  
19
31. Wilcox, B. J., Ritenour-Rodgers, K. J., Asser, A. S., Baumgart, L. E., 
Baumgart, M. A., Boger, D. L., DeBlassio, J. L., deLong, M. A., Gluke, U., 
Henz, M. E., King III, L., Merkler, K. A., Patterson, J. E., Robleski, J. J., 
Vederas, J. C., and Merkler, D. J. (1999) N-acylglycine amidation: 
Implications for the biosynthesis of fatty acid primary amides. Biochemistry 
38, 3235-3245 
32. Huang, S. M., Bisogno, T., Petros, T. J., Chang, S. Y., Zavitsanos, P. A., 
Zipkin, R. E., Sivakumar, R., Coop, A., Maeda, D. Y., De Petrocellis, L., 
Burstein, S., Di Marzo, V., and Walker, J. M. (2001) Identification of a new 
class of molecules, the arachidonyl amino acids, and characterization of one 
member that inhibits pain. J. Biol. Chem. 276, 42639-42644 
33. Wanders, R. J. A. (2004) Peroxisomes, lipid metabolism, and peroxisomal 
disorders. Mol. Genet. Metab. 83, 16-27 
34. Diczfalusy, U., Kase, B. F., Alexson, S. E. H., and Björkhem, I. (1991) 
Metabolism of prostaglandin F2α in Zellweger syndrome. Peroxisomal beta-
oxidation is a major importance for in vivo degradation of prostaglandins in 
humans. J. Clin. Invest. 88, 978-984 
35. Hankin, J. A., Wheelan, P., and Murphy, R. C. (1997) Identification of novel 
metabolites of prostaglandin E2 formed by isolated rat hepatocytes. Arch. 
Biochem. Biophys. 340, 317-330 
36. Ferdinandusse, S., Mulders, J., IJlst, L., Denis, S., Dacremont, G., Waterham, 
H. R., and Wanders, R. J. A. (1999) Molecular cloning and expression of 
human carnitine octanoyltransferase: evidence for its role in the peroxisomal 
β-oxidation of branched-chain fatty acids. Biochem. Biophys. Res. Commun. 
263, 213-218 
37. Farrell, S. O., Fiol, C. J., Reddy, J. K., and Bieber, L. L. (1984) Properties of 
purified carnitine acyltransferases of mouse liver peroxisomes. J. Biol. Chem. 
259, 13089-13095 
38. Spiekerkoetter, U., Tokunaga, C., Wendel, U., Mayatepek, E., Exil, V., Duran, 
M., Wijburg, F. A., Wanders, R. J. A., and Strauss, A. W. (2004) Changes in 
blood carnitine and acylcarnitine profiles of very long-chain acyl-CoA 
dehydrogenase-deficient mice subjected to stress. Eur. J. Clin. Invest. 34, 191-
196 
39. Cox, K. B., Hamm, D. A., Millington, D. S., Matern, D., Vockley, J., Rinaldo, 
P., Pinkert, C. A., Rhead, W. J., Russell Lindsey, J., and Wood, P. A. (2001) 
Gestational, pathologic and biochemical differences between very long-chain 
acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase 
deficiency in the mouse. Hum. Mol. Genet. 10, 2069-2077 
40. Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., 
Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., 
and Lehmann, J. M. (1999) Bile acids: natural ligands for an orphan nuclear 
receptor. Science 284, 1285-1286 
41. Wang, H., Chen, J., Holoister, K., Sowers, L. C., and Forman, B. M. (1999) 
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. 
Cell 5, 543-553 
42. Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., 
Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., and Shan, B. (1999) 
Identification of a nuclear receptor for bile acids. Science 284, 362-365 
43. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., 
Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and 
  
20
Lehmann, J. M. (1997) Fatty acids and eicosanoids regulate gene expression 
through direct interactions with peroxisome proliferator-activated receptors α 
and γ. Proc. Natl. Acad. Sci. U.S.A. 94, 4318-4323 
44. Forman, B. M., Chen, J., and Evans, R. M. (1997) Hypolipidemic drugs, 
polyunstaurated fatty acids, and eicosanoids are ligands for peroxisome 
proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U.S.A. 94, 
4312-4317 
45. Göttlicher, M., Widmark, E., Li, Q., and Gustafsson, J. Å. (1992) Fatty acids 
activate a chimera of the clofibric acid-activated receptor and the 
glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 89, 4653-4657 
46. Hostetler, H. A., Petrescu, A. D., Kier, A. B., and Schroeder, F. (2005) 
Peroxisome proliferator-activated receptor α (PPARα) interacts with high 
affinity and is conformationally responsive to endogenous ligands. J. Biol. 
Chem. 280, 18667-18682 
 
  
21
Acknowledgements:  
We thank Seamus Browne for discussions on protein expression systems. This study 
is supported by the FP6 European Union Project ‘Peroxisome’ (LSHG-CT-2004-
512018), the Swedish Research Council, Svenska Sällskapet för Medicinsk 
Forskning, AFA sjukförsäkrings jubileumsstiftelse, Åke Wibergs stiftelse, Hjärt-
Lungfonden, Lars Hiertas Minne, Fredrik och Ingrid Thurings Stiftelse, Ruth och 
Richard Julins Stiftelse, Stiftelsen Professor Nanna Svartz fond and Stiftelsen Goljes 
minne.  
  
22
FIGURE LEGENDS 
 
Fig. 1. Sequence alignment and chromosomal localization of acyl-CoA:amino 
acid N-acyltransferase (Acnat1) and bile acid-CoA:amino acid N-acyltransferase 
(Bacat). (A) Database searches identified three related genes in a cluster on mouse 
chromosome 4 B3 within 100 kb of DNA. Acnat1 and Acnat2 (acyl-CoA:amino acid 
N-acyltransferase) and Bacat (bile acid-CoA:amino acid N-acyltransferase). Each 
gene is coded by three exons. (B) Alignment of ACNAT1 and BACAT amino acid 
sequences. ACNAT1 contains a peroxisomal type 1 targeting signal of serine-lysine-
leucine (-SKL) at the carboxyterminal end. An active site serine is found at position 
235, an aspartate residue at position 325 and a histidine at position 359 of ACNAT1, 
which are marked with closed triangles, and constitute the putative catalytic triad.  
 
Fig. 2. ACNAT1 is localized in peroxisomes. 
The open reading frame of Acnat1 was cloned in-frame with green fluorescent protein 
(GFP) and expressed in either control human skin fibroblasts, or fibroblasts from a 
Zellweger patient. Immunofluorescence microscopy was carried out using a Tritc-
labeled anti-GFP antibody. (A) Punctate expression of ACNAT1 in control 
fibroblasts. (B) Diffuse expression of ACNAT1 in Zellweger fibroblasts.  
 
Fig. 3. ACNAT1 is an acyltransferase. Recombinant ACNAT1 (20 µg) was 
incubated for 4 h with 50 µM myristoyl-CoA in the presence (A) or absence (B) of 50 
mM taurine and the incubations were analyzed by ES-MS. The peak at 334.11 
corresponds to N-myristoyltaurine, the peak at 297.1 corresponds to nonadecanoic 
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acid added as an internal standard and the peak at 227.11 corresponds to myristic 
acid.  
 
Fig. 4. ACNAT1 is an acyltransferase that conjugates fatty acids to taurine. 
(A) Recombinant ACNAT1 (5 µg) was incubated for 5 min with 20 µM of various 
acyl-CoAs with the addition of bovine serum albumin (BSA) in a molar ratio of 
between 1:1.2 and 1:5.7 BSA:acyl-CoA, in the presence 50 mM taurine. 
Nonadecanoic acid (20 µM) was added as an internal standard and the samples were 
analyzed by ES-MS and quantified with respect to the internal standard and taurine 
conjugates formed. The amount of taurine conjugated fatty acid formed was 
calculated in nmol/min/mg. (B) Recombinant ACNAT1 (5 µg) was incubated for 2 
min at various concentrations of C16:0-CoA (5-50 µM) with the addition of bovine 
serum albumin (BSA) in a molar ratio of 1:2.3 BSA:acyl-CoA, and 50 mM taurine. 
Nonadecanoic acid (5 µM) was added as an internal standard and the samples were 
analyzed by ES-MS and quantified with respect to the internal standard. Km and Vmax 
were determined using Sigma Plot Enzyme Kinetics Program.  
 
Fig. 5: Acnat1 and Faah tissue expression in mouse. 
(A) The tissue expression of Acnat1 was investigated in mouse tissues using single-
plex Q-PCR. Total RNA was prepared from 3 animals, which was pooled for each 
tissue and cDNA was prepared from the pooled RNA samples. Q-PCR was run in 
triplicate for each tissue, using 18S and β-actin mRNA as a control and the relative 
amounts of mRNA were calculated using the 2-∆∆CT method. BAT; brown adipose 
tissue; WAT; white adipose tissue; proximal intestine (first 10 cm of small intestine); 
distal intestine (last 10 cm of the small intestine). (B) Total RNA was prepared from 3 
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animals and pooled. Reverse-transcriptase PCR with fatty acid amide hydrolase 
(Faah) primers was carried out on 1 µg pooled total RNA. PCR products were 
analyzed on a 2% agarose gel stained with ethidium bromide. β-actin was included as 
a positive control. 
 
Fig. 6: Role of ACNAT1 and acyl-CoA thioesterases (ACOTs) in peroxisomal 
fatty acid β-oxidation. The peroxisomal β-oxidation acts as a chain shortening 
system. Due to the presence of multiple acyl-CoA thioesterases (ACOTs) , β-
oxidation intermediates may be removed from the pathway. Under conditions when 
intra-peroxisomal acyl-CoA concentrations increase (either from uptake or increased 
levels of β-oxidation intermediates), acyl-CoA thioesterases (mainly ACOT3, 
ACOT5 and ACOT8) hydrolyze medium- and long-chain acyl-CoAs to the free acid 
and CoASH. The non-esterified fatty acids may exit the peroxisome and re-enter the 
β-oxidation pathway after activation to the CoA-ester by the long-chain acyl-CoA 
synthetase (LACS) located at the matrix side of the peroxisomal membrane. 
Alternatively, acyl-CoAs are substrate for ACNAT1, which in the presence of taurine, 
conjugates the fatty acid moiety to taurine to produce the N-acyltaurines. These N-
acyltaurines (e.g. N-palmitoyltaurine) exit the peroxisome and may act as signaling 
molecules in the liver or kidney or may be sent out in the blood for distribution to 
other organs or alternatively excreted in bile or urine. 
 
 
 
This sequence was deposited under Genbank Accession Number DQ469311. 
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